Tiziana Life Sciences disclosed that Executive Chairman and Founder Gabriele Cerrone, via Panetta Partners, purchased 42,357 common shares at $0.99 each, increasing his total holdings to 44,814,587 shares and representing about 34.93% of issued share capital. The insider purchase signals Cerrone’s strong confidence in the clinical-stage biotech’s prospects, particularly as it advances intranasal foralumab for neuroinflammatory and neurodegenerative diseases. The move reinforces Cerrone’s position as a dominant shareholder and could be interpreted by investors as governance stability and long-term commitment to the company’s strategy and lead asset. Tiziana Life Sciences continues to pursue development of its intranasal immunomodulation platform, including ongoing trials in non-active secondary progressive multiple sclerosis. These disclosures were reported across multiple outlets, confirming the breadth of coverage on the insider activity.